Handbook of experimental pharmacology

dc.contributor.author	Born, G.V.R.
dc.date.accessioned	2018-09-20T08:43:47Z
dc.date.accessioned	2023-07-20T09:13:29Z
dc.date.available	2018-09-20T08:43:47Z
dc.date.available	2023-07-20T09:13:29Z
dc.date.issued	2002
dc.identifier.isbn	978-3-642-78434-7
dc.identifier.uri	http://10.215.13.25/handle/123456789/3111
dc.description	It has been almost 20 years since the discovery by Kohler and Milstein of the technology to produce monoclonal antibodies (MAbs), a discovery that promised revolutionary changes in research, clinical diagnosis and human therapy. From today's perspective, it is fair to conclude that this promise has been realized in two areas of the three. As research tools, MAbs have been invaluable: their ability to selectively bind and localize specific antigens, detect and identify new ligands and their receptors, and agonize and/or antagonize specific molecular interactions continues to provide a useful and enabling technology to basic research endeavors. Similarly,	en
dc.language	en	en
dc.language.iso	en	en_US
dc.publisher	springer	en_US
dc.subject	paharmacology	en_US
dc.title	Handbook of experimental pharmacology	en_US
dc.type	Book	en_US